• Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

  • Aug 27 2024
  • Length: 13 mins
  • Podcast

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Listen for free

View show details

  • Summary

  • Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show More Show Less
activate_samplebutton_t1

What listeners say about Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.